Tapering from Lexapro 20mg and Luvox 100mg to Luvox Monotherapy
Taper Lexapro first while maintaining Luvox 100mg stable, reducing escitalopram by 25% of the current dose every 1-2 weeks until complete discontinuation, then continue Luvox monotherapy. 1
Rationale for This Approach
The key principle is to change only one medication at a time to isolate any withdrawal symptoms or clinical deterioration to a specific agent. Maintaining Luvox stable throughout the Lexapro taper provides continuous serotonergic coverage for your underlying anxiety or depression, minimizing the risk of symptom relapse. 1
Both escitalopram and fluvoxamine are effective SSRIs for depression and anxiety disorders, with fluvoxamine demonstrating efficacy in treating major depression with comorbid anxiety at doses of 100-300mg daily. 2 Since you're already on a therapeutic dose of Luvox (100mg), this provides adequate coverage during the transition. 3, 2
Specific Lexapro Tapering Schedule
Follow this reduction protocol for escitalopram:
- Week 1-2: Reduce from 20mg to 15mg daily (25% reduction) 1
- Week 3-4: Reduce from 15mg to 11.25mg daily (25% of current dose) 1
- Week 5-6: Reduce from 11.25mg to 8.4mg daily (approximately 25% reduction) 1
- Week 7-8: Reduce from 8.4mg to 6.3mg daily 1
- Week 9-10: Reduce from 6.3mg to 5mg daily 1
- Week 11-12: Discontinue completely 1
If withdrawal symptoms emerge at any step, slow the taper rate or temporarily return to the previous dose until symptoms subside. 1 The taper rate must be determined by your tolerance, not a rigid schedule. 4
Monitoring During the Transition
Schedule follow-up appointments every 2-4 weeks during the tapering period to assess for:
- Return of original depression or anxiety symptoms 1
- Withdrawal symptoms: anxiety, irritability, dizziness, paresthesias, headache, nausea, insomnia, or "brain zaps" 5
- Mood changes and suicidal ideation 4
More frequent contact may be needed during difficult phases of the taper. 4
Managing Withdrawal Symptoms
Common SSRI discontinuation symptoms include:
- Dizziness, headache, nausea, fatigue, irritability, and sensory disturbances 5
- These typically emerge within 1-3 days of dose reduction and resolve within 1-2 weeks 5
If withdrawal symptoms occur:
- Slow the taper rate further (reduce by 10-15% instead of 25%) 1
- Consider temporarily adding adjunctive medications: trazodone 25-50mg for insomnia, or NSAIDs/acetaminophen for headaches 4, 1
- Do not increase Luvox dose to compensate—maintain it stable 1
Maintaining Luvox Monotherapy
Continue Luvox 100mg daily unchanged throughout the entire Lexapro taper and afterward. 1 Fluvoxamine 100-300mg daily has demonstrated efficacy in treating both depression and anxiety disorders, with response rates of 38-52% in clinical trials and significant improvement in comorbid anxiety symptoms. 3, 2
Do not adjust Luvox dosing unless:
- Original symptoms return despite complete Lexapro discontinuation (may need to increase Luvox to 150-200mg) 3, 2
- Intolerable side effects emerge (may need to reduce Luvox) 3
Critical Pitfalls to Avoid
Never taper too quickly—rushing the process significantly increases withdrawal symptoms and risk of relapse. 4 Research shows that even aggressive tapers (10% every 3 days) result in only 24% completion rates. 4
Never abruptly discontinue escitalopram—this can cause severe withdrawal syndrome with significant morbidity. 5, 4
Never start adjusting Luvox simultaneously with tapering Lexapro—this makes it impossible to determine which medication is causing any emerging symptoms. 1
Never abandon the patient if tapering is difficult—maintain the therapeutic relationship and consider pausing the taper if needed. 4
Special Considerations
If you experience significant withdrawal symptoms despite slow tapering:
- Consider an even more gradual reduction (10% of current dose every 2-4 weeks instead of 25%) 4
- Pauses in the taper are acceptable and often necessary when withdrawal symptoms emerge 4
- The entire process may take 3-6 months, which is appropriate for safe discontinuation 4, 1
Cognitive-behavioral therapy (CBT) during the taper significantly increases success rates and should be incorporated if available. 4